Cochlear Implant Lead Drug Release Using a 3D Cochlea Profile
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cochlear implant systems face challenges in effectively delivering drugs to address trauma and preserve residual hearing, as existing drug delivery methods often result in suboptimal timing and location of drug release, leading to inflammation and potential damage to intracochlear structures.
Innovation Solution
An individualized drug delivery profile is generated using a 3D cochlea model and procedure data to control the release of drugs from a stimulating lead, ensuring targeted and localized distribution based on the recipient's cochlea size, lead position, and insertion history.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs are passively eluted from the electrode lead into the perilymph, then the trauma is treated, but the drugs are released at suboptimal timing and location
Solution Approach 1:
The system performs preliminary actions by pre-programming the drug delivery profile before implantation. The processor is configured to release drugs according to a predetermined schedule and pattern that is optimized before the procedure, ensuring correct timing and location of drug release without requiring real-time adjustment during implantation.
Solution Approach 2:
The system incorporates feedback mechanisms where the processor monitors conditions within the cochlea and adjusts drug release accordingly. This closed-loop control ensures that drugs are released at the precise timing and location needed, correcting deviations from the optimal delivery pattern based on real-time or near-real-time information.
2Object-affected harmful factors
If repeated transtympanic administrations of anti-inflammatory drugs are performed, then inflammation is treated, but off-target effects and significant burden occur
Solution Approach 1:
The system applies local quality by delivering drugs directly to the specific location within the cochlea where inflammation occurs, rather than systemic administration. The processor is configured to release drugs at targeted locations through the electrode lead, ensuring the anti-inflammatory effect is localized to the affected area while minimizing exposure to other parts of the body.
Solution Approach 2:
The electrode lead serves as an intermediary device that enables direct drug delivery to the cochlear space. Instead of using transtympanic administration which requires repeated invasive procedures, the implantable electrode lead acts as a mediator that can deliver drugs internally, reducing patient burden and avoiding off-target effects associated with repeated external administrations.
3Object-affected harmful factors
If intracochlear administrations are performed post-implantation, then inflammation is treated, but damage to the implanted device and disruption of the local environment occur
Solution Approach 1:
The electrode lead serves as an intermediary device that enables direct drug delivery to the cochlear space. Instead of using transtympanic administration which requires repeated invasive procedures, the implantable electrode lead acts as a mediator that can deliver drugs internally, reducing patient burden and avoiding off-target effects associated with repeated external administrations.
Solution Approach 2:
The system enables self-service by allowing the implanted device to administer drugs autonomously according to the pre-programmed profile. The processor automatically releases drugs at the appropriate times and locations without requiring external intervention or repeated surgical procedures, thereby maintaining device integrity and avoiding disruption to the local environment.
4Reliability
If an individualized drug delivery profile is implemented, then preservation of intracochlear structures is enhanced, but device complexity increases
Solution Approach 1:
The system performs preliminary actions by pre-programming the drug delivery profile before implantation. The processor is configured to release drugs according to a predetermined schedule and pattern that is optimized before the procedure, ensuring correct timing and location of drug release without requiring real-time adjustment during implantation.
Solution Approach 2:
The system utilizes parameter changes by adjusting drug release characteristics (timing, location, amount) based on individual patient anatomy and procedure data. The processor is configured to modify delivery parameters according to the specific 3D cochlea model and lead insertion details, enabling personalized therapy while managing complexity through automated parameter optimization.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An exemplary system comprises a memory that stores instructions and a processor communicatively coupled to the memory and configured to execute the instructions to perform a process. The process may comprise accessing an individual three-dimensional ("3D") cochlea model of a cochlea of a recipient of a cochlear implant system that includes a stimulating lead inserted into the cochlea during a lead insertion procedure, generating, based on the individual 3D cochlea model and procedure data associated with one or more lead insertion procedures performed with respect to one or more other recipients, an individualized drug delivery profile for the recipient, and transmitting a command to the cochlear implant system to cause release of a drug from the stimulating lead in accordance with the individualized drug delivery profile.